Briacell Therap (NASDAQ:BCTX) Stock Price Down 5.4% – Time to Sell?

Briacell Therap (NASDAQ:BCTX) dropped 5.4% during trading on Thursday. The company traded as low as $3.31 and last traded at $3.31. Approximately 62,599 shares changed hands during mid-day trading, an increase of 9% from the average daily volume of 57,177 shares. The stock had previously closed at $3.50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Briacell Therap in a report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Briacell Therap Stock Performance

The business has a 50-day simple moving average of $3.77 and a two-hundred day simple moving average of $3.85. The company has a market capitalization of $26.45 million, a price-to-earnings ratio of -0.33 and a beta of 1.21.

Briacell Therap (NASDAQ:BCTX) last released its earnings results on Wednesday, October 28th. The company reported ($1.50) earnings per share (EPS) for the quarter.

Briacell Therap Company Profile

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its research is centered on treatments designed to stimulate a patient’s immune system to recognize and attack tumor cells, with an emphasis on advanced breast cancer and other solid tumors.

The company’s lead technology includes Bria-IMT, an off-the-shelf, whole-cell immunotherapy derived from a breast cancer cell line. BriaCell has also been developing Bria-OTS, a personalized immunotherapy approach intended to match treatment with a patient’s human leukocyte antigen profile.